GBI Research
GBI Research Market Research Reports
| Title | published | price | |
|---|---|---|---|
Respiratory Tract Infections Drug Development Pipeline Review, 2018By GBI Research
Respiratory Tract Infections Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for respiratory tract infections. It provides comprehensive information on the therapeuti ... |
31-Jul-2018 | $3995 | |
Mucopolysaccharidosis Disorders Drug Development Pipeline Review, 2018By GBI Research
Mucopolysaccharidosis Disorders Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for mucopolysaccharidosis disorders, a group of inherited lysosomal storage disorders. ... |
30-Jul-2018 | $3995 | |
Diarrhea and Constipation Drug Development Pipeline Review, 2018By GBI Research
Diarrhea and Constipation Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for diarrhea and constipation. It provides comprehensive information on the therapeutics und ... |
30-Jul-2018 | $3995 | |
Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the MarketBy GBI Research
Colorectal cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. The five-year prevalence population for CRC in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the growi ... |
01-Jul-2018 | $4995 | |
Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast CancerBy GBI Research
Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer Summary Breast cancer remains a major global healthcare concern despi ... |
01-Jul-2018 | $6995 | |
Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust PipelineBy GBI Research
Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline Summary Cancer immunotherapy, which can predominantly be classed as a form ... |
01-Jul-2018 | $4995 | |
Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018By GBI Research
Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for diabetes and associated metabolic conditions. It provides comprehensi ... |
29-Jun-2018 | $3995 | |
Menopausal Disorders Drug Development Pipeline Review, 2018By GBI Research
Menopausal Disorders Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for menopausal disorders. It provides comprehensive information on the therapeutics under develop ... |
29-Jun-2018 | $3995 | |
Hepatitis Drug Development Pipeline Review, 2018By GBI Research
Hepatitis Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for hepatitis infections. It provides comprehensive information on the therapeutics under development and ke ... |
29-Jun-2018 | $3995 | |
Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the MarketBy GBI Research
Psoriasis is a common, chronic inflammatory skin condition affecting around 2-3% of the world’s population. While the main cause of psoriasis remains uncertain, immunologic, genetic, and environmental factors appear to play a role. Common sy ... |
01-Jun-2018 | $4995 | |
Mosquito-borne Diseases Drug Development Pipeline Review, 2018By GBI Research
Mosquito-borne Diseases Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for mosquito-borne diseases and comprehensive information on the therapeutics under developmen ... |
24-May-2018 | $3995 | |
Ocular Cancer Drug Development Pipeline Review, 2018By GBI Research
Ocular Cancer Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for ocular cancer and comprehensive information on the therapeutics under development and key players in ... |
23-May-2018 | $3995 | |
Inflammatory Skin Diseases Drug Development Pipeline Review, 2018By GBI Research
Inflammatory Skin Diseases Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for inflammatory skin disorders and comprehensive information on the therapeutics under dev ... |
22-May-2018 | $3995 | |
Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive SymptomsBy GBI Research
Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms Summary Schizophrenia is a chronic mental disorder that affects 1% of the population - equivalen ... |
01-May-2018 | $6995 | |
Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising PrevalenceBy GBI Research
Breast cancer is the second most common cancer in the world overall, and the most common cancer in women. When diagnosed at a very early stage, the prognosis is positive, with a five-year survival rate of nearly 90%. However, in the later stages o ... |
01-May-2018 | $4995 | |
Influenza A Viral Infections Drug Development Pipeline Review, 2018By GBI Research
This report provides an overview of the pipeline landscape for influenza A viral infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A H3N2, H1N1 ... |
30-Apr-2018 | $3995 | |
Cognitive Impairment Disorders Drug Development Pipeline Review, 2018By GBI Research
Cognitive Impairment Disorders Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therap ... |
01-Apr-2018 | $3995 | |
Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular DiseaseBy GBI Research
Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease Summary ... |
01-Apr-2018 | $6995 | |
HAE Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Ongoing Shift towards Plasma-Derivative Products and Expected Launch of Premium TherapiesBy GBI Research
Hereditary Angioedema (HAE) is a rare genetic disorder caused by a lack of a sufficient amount of a protein called C1 esterase inhibitor (C1-INH), which plays a role in immune system function, blood clotting, and bleeding. With insufficient C1-INH ... |
31-Mar-2018 | $4995 | |
Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster DrugsBy GBI Research
Summary Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations. Although they are often disparate in terms of their symptoms and key p ... |
31-Mar-2018 | $4995 | |
- + 1 888 391 5441
- [email protected]
